Prof Mark Beresford's Profile
Professor Mark Beresford is a consultant clinical oncologist and departmental clinical lead at the Royal United Hospital Bath and a visiting professor at the University of Bath. He specialises in the treatment of breast and urological cancers.
Professor Beresford is a graduate of both Cambridge and Oxford Universities and undertook his specialist oncology training in London (UCLH, Charing Cross and Mount Vernon Hospitals).
He has a DM from Oxford University for research into the assessment of response to chemotherapy using functional imaging techniques. He is author of over 50 peer-reviewed publications including scientific papers and textbooks.
Professor Beresford is chief investigator on numerous national and international clinical trials. He is a member of the NCRI Breast Cancer Advanced Disease trials subgroup, has advised NICE at scoping meetings and technology appraisals and is a committee member of the British Uro-oncology Group and Cancer Research at Bath.
He is co-founder of the UK Breast Cancer Group and chair of the annual UKBCG meeting. He chairs the West of England breast cancer site specific group.
He is vice-chair of the CRUK population research committee.
Professor Beresford is a graduate of both Cambridge and Oxford Universities and undertook his specialist oncology training in London (UCLH, Charing Cross and Mount Vernon Hospitals).
He has a DM from Oxford University for research into the assessment of response to chemotherapy using functional imaging techniques. He is author of over 50 peer-reviewed publications including scientific papers and textbooks.
Professor Beresford is chief investigator on numerous national and international clinical trials. He is a member of the NCRI Breast Cancer Advanced Disease trials subgroup, has advised NICE at scoping meetings and technology appraisals and is a committee member of the British Uro-oncology Group and Cancer Research at Bath.
He is co-founder of the UK Breast Cancer Group and chair of the annual UKBCG meeting. He chairs the West of England breast cancer site specific group.
He is vice-chair of the CRUK population research committee.